AlphAIAlphAI — Financial news for AI agents
manufacturingchemist.comNOV 32 min read

Merck KgaA divests US CDMO business to Lonza

Merck KGaA is selling its US contract development and manufacturing organization (CDMO) business to Lonza for an estimated low- to mid-triple-digit million Swiss francs. The deal includes five US sites and around 1,100 employees, expected to close mid-2024. Lonza anticipates $300m in sales from these facilities by 2028. Merck aims to focus on innovation-driven life sciences businesses, according to the company.

Original reporting
manufacturingchemist.com
Published Nov 3, 2026, 11:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 12:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Merck KgaA divests US CDMO business to Lonza — source image
Source · manufacturingchemist.com
Decision brief

The 30-second read

Med
01

Why it matters

The transaction expands Lonza's US footprint and capabilities but is projected to have minimal effect on its overall financials.

02

Market read

A material M&A deal in the biotech manufacturing space with limited immediate price impact.

03

What to watch

Integration risks and potential cultural differences between the German and Swiss operations could affect execution.

Relevance 8/10Novelty 8/10Timing: today

Background

Merck KGaA is divesting its US CDMO business to Lonza, marking a strategic shift toward core life‑science activities.

Market effects

Sector

Strengthens Lonza's position in the CDMO sector, potentially prompting consolidation among peers.

Regional

Adds capacity in the US biotech manufacturing landscape.

Global

Highlights ongoing consolidation in global contract manufacturing services.

Counterpoint

What could challenge this read

The deal may be overpriced relative to the modest revenue contribution, risking overvaluation of Lonza.

Key entities

  • company
    Merck KGaA

    German life‑science company selling its US CDMO business.

  • company
    Lonza

    Swiss contract manufacturer acquiring the CDMO assets.

Read at source← All news

StoryLonza to acquire Merck KGaA’s U.S. CDMO network

Also covered by

6 outlets

Related articles

NOV 3
$MRKMedAI 9/10

Merck Sells Its CDMO Business to Lonza

Merck agreed to sell its CDMO business to Lonza for mid-three-digit millions of euros. The deal, expected to close in mid-2027, includes five U.S. sites. Merck aims to focus on innovation-driven businesses, while Lonza expands its CDMO operations. The transaction is subject to regulatory approvals.

chemanager-online.com2 min
NOV 3
HighAI 8/10

Lonza buys 5 sites from Germany’s Merck to more than double US footprint

Lonza agreed to buy five U.S. manufacturing sites from Merck KGaA for 100-600 million Swiss francs, expanding its U.S. footprint to nine sites. The deal, expected to close mid-2024, adds 1,100 employees and is projected to generate 250 million francs in annual sales by 2028. Lonza gains cancer and gene therapy production capabilities, while Merck focuses on drug development.

investing.com2 min
NOV 3
MedAI 9/10

Merck charts course out of CDMO business with Lonza sale

Merck KGaA is selling its CDMO business to Lonza for a mid-triple-digit million-euro amount, including five US facilities and 1,100 employees. The deal aims to sharpen Merck's life sciences focus and free up resources for other areas, including pharmaceuticals. Lonza expects the acquisition to add $300 million in annual revenue starting in 2028. The transaction is expected to close in mid-2027.

pharmaphorum.com2 min
NOV 3
MedAI 8/10

Lonza to acquire five US manufacturing sites from Merck KGaA

Lonza will acquire five US manufacturing sites from Merck KGaA for low- to mid-triple-digit millions of Swiss francs. The deal, expected to close in mid-2027, will expand Lonza's US presence and add 1,100 employees. The sites focus on various pharmaceutical technologies, with Lonza expecting them to contribute around SFr250m in sales by 2028. The acquisition aligns with Lonza's growth strategy, according to the company.

pharmaceutical-technology.com2 min